Loading
Halozyme Therapeutics, Inc. Stock: price and insider trades · United States
Insider Decl.
895
Thresholds
n/a
Buy Volume
€683,056
3 ops. · all time
Sell Volume
€182M
344 ops. · all time
Who traded when
BuySaleHelen Torley93 sales
Bernadette Connaughton11 sales
Jeffrey William Henderson8 sales
Matthew L. Posard8 sales
Michael J. LaBarre6 sales
Cortney Caudill4 sales
+2 other insiders
Since the insiders bought
- +183.6%Entry US$15.57 · Close at T+365 US$44.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Halozyme Therapeutics, Inc. Buy (bullish), based on 9 analysts. Average price target: US$108.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,058 of 26,280 companies
55.7
score / 100
Value37
Quality75
FCF yld2.5%
Earn yld2.2%
EV/EBITDA28.5x
ROE174%
Gross mgn61%
Net mgn23%
Debt/EBITDA3.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$124.83
Analyst consensus
9 analystsBuy
US$78.00Target US$108.78(-13%)US$130.00
Income statement
RevenueUS$1.4B
Gross profitUS$855.9M61% margin
EBITDAUS$573.1M41% margin
Net incomeUS$316.9M24.9% margin
Valuation
PER (trailing)36.5x
PER (forward)11.7x
P/Book99.2x
Beta0.88
Balance sheet & cash
Market capUS$14.2B
Total debtUS$2.1B
Free Cash FlowUS$356.8M
Debt / Equity1518%
Profitability & ownership
ROE173.7%
ROA25.5%
% insiders1.1%
% institutions113.6%
Last declaration on 8 October 2026
Declarations895 total
3,796 shares0Common StockSEC:0001159036-26-000139:0
20,000 shares@ US$18.410.0029% mcap1.2% of flowCommon StockSEC:0001159036-26-000140:0
2,300 shares@ US$107.9020.0020% mcap0.8% of flowCommon StockSEC:0001159036-26-000140:1
6,000 shares@ US$109.3340.0052% mcap2.1% of flowCommon StockSEC:0001159036-26-000140:2
9,920 shares@ US$109.8910.0086% mcap3.5% of flowCommon StockSEC:0001159036-26-000140:3
1,780 shares@ US$110.8120.0016% mcap0.6% of flowCommon StockSEC:0001159036-26-000140:4
20,000 shares@ US$18.410.0029% mcap1.2% of flowCommon StockSEC:0001159036-26-000140:5
8,600 shares@ US$111.0310.0075% mcap3.1% of flowCommon StockSEC:0001159036-26-000140:6
10,300 shares@ US$111.8390.0091% mcap3.7% of flowCommon StockSEC:0001159036-26-000140:7
900 shares@ US$112.780.0008% mcap0.3% of flowCommon StockSEC:0001159036-26-000140:8
200 shares@ US$113.6930.0002% mcap0.1% of flowCommon StockSEC:0001159036-26-000140:9
20,000 shares@ US$18.410.0029% mcap1.2% of flowCommon StockSEC:0001159036-26-000140:10
4,810 shares@ US$108.1790.0041% mcap1.7% of flowCommon StockSEC:0001159036-26-000140:11
3,090 shares@ US$108.9080.0027% mcap1.1% of flowCommon StockSEC:0001159036-26-000140:12
11,900 shares@ US$109.9950.010% mcap4.2% of flowCommon StockSEC:0001159036-26-000140:13
200 shares@ US$110.510.0002% mcap0.1% of flowCommon StockSEC:0001159036-26-000140:14
1,100 shares@ US$109.5690.0009% mcap2.8% of flowCommon StockSEC:0001159036-26-000133:2
730 shares@ US$107.1680.0006% mcap1.8% of flowCommon StockSEC:0001159036-26-000133:0
3,300 shares@ US$108.4540.0028% mcap8.3% of flowCommon StockSEC:0001159036-26-000133:1
100 shares@ US$110.040.0001% mcap0.3% of flowCommon StockSEC:0001159036-26-000133:3
1,169 shares0Restricted Stock UnitsSEC:0001159036-26-000136:0
3,100 shares@ US$106.1320.0023% mcap7.5% of flowCommon StockSEC:0001159036-26-000123:0
8,896 shares@ US$108.040.0068% mcap21.9% of flowCommon StockSEC:0001159036-26-000123:2
3,000 shares@ US$106.8280.0023% mcap7.3% of flowCommon StockSEC:0001159036-26-000123:1
4,000 shares@ US$108.9910.0031% mcap9.9% of flowCommon StockSEC:0001159036-26-000123:3
25 of 895 declarations
About Halozyme Therapeutics, Inc.
Randal J. Kirk, listed as a 10% Owner at Halozyme Therapeutics, Inc., reported the three largest sales in the record: EUR 7,014,600 and EUR 4,789,746 on August 22, 2018, then EUR 3,959,042 on August 28, 2018. Kirk has 57 filings, 36 of them sales. In total, 344 sales weigh EUR 181.9 million (median EUR 400,600).
There are 3 purchases, worth EUR 683,056 (median EUR 227,899), or 1% of open-market trades, and they carry the same signature: Kenneth J. Kelley, Director, bought EUR 228,059, EUR 227,899 and EUR 227,099, all on March 19, 2020. Helen Torley, PRESIDENT AND CEO, is the most frequent filer, with 340 filings including 163 sales.
Read moreShow less
This US healthcare and pharma company, valued at USD 13.9 billion and 1.1% held by insiders, has filed 895 times from 30 filers, including 293 option exercises and 221 grants. 2026 holds 124, against 27 in 2017. The first publication dates from January 4, 2016 and the latest from October 8, 2026, with a median delay of 1 day. Over the last twelve months: 145 filings, of which 77 sales and no purchase.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
